Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis

By afschroeder • September 6, 2026

Hoffman R, Watanabe M, Martínez E, Zanni MV, Pozniak A, Shakil SS, McCallum S, Chu SM, Srinivasa S, Malvestutto CD, Fichtenbaum CJ, Bloomfield GS, Lu AB, Aberg JA, Currier JS, Lu MT, Douglas PS, Ribaudo HJ, Grinspoon SK. Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis. Open Forum Infect Dis. 2026 Aug 20;13(9):ofag507. doi: 10.1093/ofid/ofag507. PMID: 42699213; PMCID: PMC13542724.

Tags: Cardiology/Epi, cardiovascular disease, HIV, Hypertension, hypertension control, Infectious Diseases, Publications

Lipids and lipoproteins in calcific aortic valve disease

Aksoy O, Tintut Y, Demer LL. Lipids and lipoproteins in calcific aortic valve disease. Curr Opin Lipidol. 2026 Oct 1;37(5):185-190. doi: 10.1097/MOL.0000000000001053. Epub 2026 Aug[...]

Lipids in endothelial-to-mesenchymal transition

Tripsas CK, Tsai AY, Hsu JJ. Lipids in endothelial-to-mesenchymal transition. Curr Opin Lipidol. 2026 Oct 1;37(5):177-184. doi: 10.1097/MOL.0000000000001051. Epub 2026 Aug 12. PMID: 42592967.

Atherosclerosis: cell biology and lipoproteins

Navab M. Atherosclerosis: cell biology and lipoproteins. Curr Opin Lipidol. 2026 Oct 1;37(5):169. doi: 10.1097/MOL.0000000000001055. Epub 2026 Sep 3. PMID: 42698378.